HIV Antigen definition

HIV Antigen means any [***] that is intended to stimulate an immune response in humans against HIV.
Sample 1Sample 2Sample 3
HIV Antigen means the HIV GP120 based recombinant fusion protein which is further described in Part 5 of Schedule 2 of this Agreement;
Sample 1Sample 2
HIV Antigen means the Human Immunodeficiency Virus antigen.
Sample 1

Examples of HIV Antigen in a sentence

  • Rationale: Modify the description of the Clinical Laboratory Tests Panel to be accurate.9.5 Safety Evaluations and Attachment 5Addition of HIV Antigen to Clinical Laboratory Tests Panel HIV antigen/antibodyModified the description of the Urinalysis panel footnote.d. Microscopic examination of RBC, WBC, casts, bacteria and such will be conducted if protein and/or blood are detected during urinalysis.

  • OD R3 =OD (C1) + OD (D1) + OD (E1) 3Calculate the cut-off value:CO = OD R3 + 0.200 The presence or absence of detectable HIV Antigen or antibodies to HIV-1 and/or HIV-2 is determined by comparing the absorbance measured for each sample to the calculated cut-off value.

  • For detection of HIV infection, 3rd generation Microlisa was used to detect the HIV Antigen and antibody in donor serum.

  • The BioPlex 2200 HIV Antigen Calibrator contains no HIV antibodies and is the negative calibrator for the antibody detection bead populations.

  • FDA Approves First Diagnostic Assay to Detect Both HIV Antigen and Antibodies.

  • Similarly, the BioPlex 2200 HIV Antigen Calibrator contains HIV-1 p24 antigen and has an Index based on reference material.

  • Positive HIV Antigen screening test will be confirmed by nucleic acid testing.

  • OD R3 = OD (C1) + OD (D1) + OD (E1) 3 [EN] 11Calculate the cut-off value:CO = OD R3 + 0.200 The presence or absence of detectable HIV Antigen or antibodies to HIV-1 and/or HIV-2 is determined by comparing the absorbance measured for each sample to the calculated cut-off value.

  • Table 1: Detection of HIV Antigen Genotypes *Isolates tested after dilution to 200,000 RNA copies/mL in defibrinated, delipidized plasma.

  • Arabidopsis thaliana The concentration levels of the p24 protein in different parts of the plant were determined by enzyme-linked immunosorbent assay (ELISA), using the INNOTEST® HIV Antigen mAb (Innogenetics, Gent, Belgium) according to the manufacturer’s protocol.

Related to HIV Antigen

  • Antigen means a substance recognized by the body as being foreign; it results in the production of specific antibodies directed against it.

  • Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.

  • Licensed Compound means [***].

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Opioid antidote means any drug, regardless of dosage amount or method of administration, which has been approved by the United States Food and Drug Administration (FDA) for the treatment of an opioid overdose. “Opioid antidote” includes, but is not limited to, naloxone hydrochloride, in any dosage amount, which is administered through nasal spray or any other FDA-approved means or methods.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.

  • Opioid antagonist means a drug that binds to opioid

  • Diagnostic Product means any test or assay for diagnosing or detecting a disease, disorder, medical condition, or symptom.

  • Product Candidate means any pharmaceutical product developed, manufactured and/or tested by or on behalf of the Company that has not received a Regulatory Authorization for commercial distribution other than in connection with pre-clinical or clinical trials.

  • Development Candidate means a Collaboration Compound designated by Biogen Idec as a Development Candidate in accordance with Section 2.6.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Receptor means enclosed spaces, conduits, protected groundwater sources, drinking and non-drinking water wells, surface water bodies, and public water systems which when impacted by chemicals of concern may result in exposure to humans and aquatic life, explosive conditions or other adverse effects on health, safety and the environment as specified in these rules.

  • Biological product means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

  • Biosimilar means a biological product that is highly similar to a specific reference biological

  • Biosimilar Product means, with respect to a Licensed Product in any country, any biosimilar product sold by a Third Party not authorized by or on behalf of Celgene, its Affiliates or Sublicensees, (a) that is a biosimilar biological product, as defined in 21 USC 379j-51 (or any successor or replacement thereof), a similar biological medicinal product, as defined in Annex I to Directive 2001/83/EC (or any successor or replacement thereof), or any similar biosimilar or generic product under the Laws of any country or jurisdiction, or (b) regarding which Regulatory Approval is obtained by referencing Regulatory Data of such Licensed Product.

  • Reference biological product means the single biological product licensed pursuant to 42 U.S.C.

  • Vaccine means a specially prepared antigen which, upon administration to a person, will result in immunity and, specifically for the purposes of this rule, shall mean influenza and pneumococcal vaccines.

  • Biological Material means any material containing genetic information and capable of reproducing itself or being reproduced in a biological system;

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • HIV means human immunodeficiency virus.

  • Exempt compound means the same as defined in Rule 2.

  • Biological Materials means certain tangible biological materials that are necessary for the effective exercise of the Patent Rights, which materials are described on Exhibit A, as well as tangible materials that are routinely produced through use of the original materials, including, for example, any progeny derived from a cell line, monoclonal antibodies produced by hybridoma cells, DNA or RNA replicated from isolated DNA or RNA, recombinant proteins produced through use of isolated DNA or RNA, and substances routinely purified from a source material included in the original materials (such as recombinant proteins isolated from a cell extract or supernatant by non-proprietary affinity purification methods). These Biological Materials shall be listed on Exhibit A, which will be periodically amended to include any additional Biological Materials that Medical School may furnish to Company.